BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Biocancell Therapeutics Ltd. (TASE:BICL), which researches and develops cancer drugs, has reported a successful clinical trial on bladder cancer patients classified as high-risk patients. The company's treatment was proved to be effective and safe in the trial. The US Food and Drug Administration requires success in the trial as a condition for advancing to Phase III clinical trials for BC-819, the company's leading product, which is administered together with BCG, the standard treatment. The company's share price rose 9.5% in afternoon trading on the TASE.

The clinical trials demonstrated for the first time the safety and effectiveness of the combined treatment including BCG on high-risk bladder cancer patients. 17 patients were treated in the trial with three treatments regimens, following removal of all the malignant tumors in the bladder.

The results of the trial were that 11 of the 17 patients (65%) had no recurrence of the malignant tumor for three months from the beginning of the treatment. No severe side effects related to the treatment were diagnosed during the trial.

BioCancell said it planned to continue preparations for further clinical trials, including the production processes necessary for Phase III of clinical trials for BC-819 and promotion of business and commercial development of the drug. BioCancell is holding initial and non-binding meetings, and is considering a number of possibilities for commercial development of BC-819 as a treatment for bladder cancer. The company emphasizes that at this stage, there is no certainty if, when, and under what conditions the negotiations for commercial development of BC-819 will yield positive results.

BioCancell CEO Jonathan Burgin said today, "We're very satisfied with the clinical trial results and the demonstration of the drug's effectiveness and safety for high-risk bladder cancer patients. The clinical results are an important indication that use of BC-819 in combination with BCG is safe. The effectiveness achieved in the trial constitutes further proof of the clinical successes hitherto achieved, and matches the findings in the Phase IIB clinical trial that recurrence of malignant tumors was prevented for three months in 64% of patients."

Published by Globes [online], Israel business news - www.globes-online.com - on September 23, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

SatixFy CEO Nir Barkan credit: Ariel Barkan Canada's MDA Space to buy Israeli satcom co SatixFy

MDA Space will pay $269 million for the Israeli company, including taking on a $76 million debt and a 75% premium on SatixFy's closing price on Nasdaq yesterday.

Raising dollars credit: Shutterstock Israeli startups raised over $1b in March

Israeli privately-held tech companies have raised $2.1 billion in the first three months of 2025, according to IVC-LeumiTech, up 24% from the corresponding quarter of 2024.

Terminal 1 credit: Personal image Terminal 1 reopening revives Israel low-cost fare options

With the opening of the terminal for international flights, the Irish low-cost airline Ryanair has returned to Israel and with it, double-digit US dollar round-trip fares.

Arkady Volozh  credit: Shlomi Yosef Analysts see Israel-linked Nebius challenging CoreWeave

Nebius, founded by Yandex founder Arkady Volozh, operates in CoreWeave's AI server market, but is growing "more rationally", and has far less debt.

Bezalel Smotrich and Amir Yaron credit: Knesset Spokesperson and Tali Bogdanovsky Retail chains, credit card cos could soon act as banks

Israel's financial regulators have proposed that supermarket chains, credit card companies and investment houses will be able to accept deposits and offer credit.

Elbit Systems rocket launcher  credit: Elbit Systems Elbit Systems wins $130m European rocket order

The order is for the supply of rockets for Elbit's Precise and Universal Launching System (PULS), which has an effective range of up to 300 kilometers.

Nvidia VP Ali Kani credit: Nvidia Nvidia intensifies efforts to compete with Mobileye

"Globes" talks to Nvidia VP and automotive team head Ali Kani about the chipmaker's autonomous vehicle activities and assesses the threat to Mobileye.

Fitch ratings agency credit: Shutterstock Fitch reaffirms Israel's A rating with negative outlook

The ratings agency said, "The negative outlook reflects rising public debt, domestic political and governance challenges and uncertain prospects for the conflict in Gaza."

Tamar rig credit: PR Sovereign Wealth Fund earned handsome returns in 2024

Israel's Sovereign Wealth Fund, known as the Citizens' Fund, had assets worth about $2 billion at the end of 2024, the Ministry of Finance reports.

Fencing goes up Petah Tikva's Segula neighborhood  credit: NTA Work on Metro to begin in Petah Tikva

The first work on the Tel Aviv Metropolitan underground railways system will begin on the M2 line depot in Petah Tikva.

Startups credit: Shutterstock/NicoElNino IVC-LeumiTech: Tech fund raising jumps 24% in Q1

Israeli privately-held tech companies raised $2.13 billion in the first quarter of 2025, up 24% from the corresponding quarter of 2024, but down 12% from the preceding quarter.

Miri Regev and Yitzhak Rochberger credit: Yediot Ahronot/ Reuven Kapuchinsky and Amit Shabi Ramat Hasharon wants railway station for the Mossad

Ramat Hasharon is pushing for a station in Glilot neat the Mossad headquarters, even though a new station is also planned for Glilot South, 1.6 kilometers away.

Prime Minister Benjamin Netanyahu credit: Reuven Kastro Police call Netanyahu for testimony as aides arrested

Jonatan Urich and Eli Feldstein are being held over alleged payments received from Qatar while working in the prime minister's bureau.

Highcon chairperson Shlomo Nimrodi  credit: PR Packaging tech co Highcon winding down

The company, which numbers Benny Landa and JVP among its investors, is laying off most of its workforce, having lost 99.9% of its value since its flotation.

MK Almog Cohen  credit: Danny Shem-Tov, Knesset Spokesperson's Office Netanyahu halts Nevatim airport bill

Legislation mandating construction of an airport at Nevatim, near Beersheva, is ready for final Knesset approval, but the prime minister blocked it after a security cabinet meeting.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018